U.S. markets close in 40 minutes
  • S&P 500

    4,099.92
    +49.09 (+1.21%)
     
  • Dow 30

    33,211.19
    +352.16 (+1.07%)
     
  • Nasdaq

    12,196.83
    +183.36 (+1.53%)
     
  • Russell 2000

    1,792.99
    +24.61 (+1.39%)
     
  • Crude Oil

    75.42
    +1.05 (+1.41%)
     
  • Gold

    1,987.50
    -10.20 (-0.51%)
     
  • Silver

    24.17
    +0.19 (+0.78%)
     
  • EUR/USD

    1.0850
    -0.0059 (-0.54%)
     
  • 10-Yr Bond

    3.4940
    -0.0570 (-1.61%)
     
  • GBP/USD

    1.2333
    -0.0057 (-0.46%)
     
  • USD/JPY

    132.7610
    +0.0720 (+0.05%)
     
  • Bitcoin USD

    28,340.74
    +405.31 (+1.45%)
     
  • CMC Crypto 200

    620.20
    +5.99 (+0.98%)
     
  • FTSE 100

    7,631.74
    +11.31 (+0.15%)
     
  • Nikkei 225

    28,041.48
    +258.55 (+0.93%)
     

Global COVID-19 vaccine supply "incredibly tight", COVAX needs funds - Gavi

GENEVA, April 15 (Reuters) - The global supply of COVID-19 vaccine is "incredibly tight" and the COVAX dose-sharing facility is unlikely to procure much more supply in 2021 than doses already reserved, the Gavi vaccine alliance ceo Seth Berkley said on Thursday.

"We urgently need commitments of a further $2 billion from donors and $1 billion from countries supported by multilateral development banks. Included in the $2 billion we ask for is $150 million from the private sector," Berkley told an event, referring to a funding target for June.

Stanley Erck, Novavax ceo, said that the U.S.-based company had vaccine production capabilities in more than 20 facilities and that it was "well on our way to securing regulatory authorisations around the world". (Reporting by Stephanie Nebehay in Geneva and Michelle Nichols in New York;)